Our findings indicate that hArg-LL-37 can be used as a therapeutic replacement for LL-37 in pathological inflammatory conditions such as psoriasis and rheumatoid arthritis, in which citrullination of the native peptide compromises its antibacterial and immunoregulatory activities [15,16]. This evidence concerns the gene CAMP and psoriasis.